Hi Allan - I believe the idea is that TKTX will need to employ a key process patented by CEGE to produce the equivalence of Epogen, if the former wins the case. Therefore, the latter will garner royalty payment. However, I do not think CEGE business model is built on this case. That is to say, if TKTX wins, CEGE will have extra gravy, but none of the previous ERs I ve read brought up this point. Instead, CEGE core is GVAX, with a huge AAV patent portfolio, plus its strong cash position and ABGX holding, and milestone payment from JTC. It is possible some people may build this potential deal with TKTX in their expectation, I don't know. If they did though, it didn't reflect in the stk price.
So, my guess is that it is only tangentially affecting CEGE, the real players are the two opponents
best, Bosco |
